Few studies have evaluated the impact of the viral challenge route on protection against a heterologous simian immunodeficiency virus (SIV) challenge. We vaccinated seven macaques with a live attenuated SIV that differed from SIVmac239⌬nef by 24 amino acids, called m3KO⌬nef. All animals were protected from an intrarectal SIVmac239 challenge, whereas only four animals were protected from subsequent intravenous SIVmac239 challenge. These data suggest that immune responses elicited by vaccination with live attenuated SIV in an individual animal can confer protection from intrarectal challenge while remaining insufficient for protection from intravenous challenge.
IMPORTANCEOur study is important because we show that vaccinated animals can be protected from a mucosal challenge with a heterologous SIV, but the same animals are not necessarily protected from intravenous challenge with the same virus. This is unique because in most studies, either vaccinated animals are challenged multiple times by the same route or only a single challenge is performed. An individually vaccinated animal is rarely challenged multiple times by different routes, so protection from different challenge routes cannot be measured in the same animal. Our data imply that vaccine-elicited responses in an individual animal may be insufficient for protection from intravenous challenge but may be suitable for protection from a mucosal challenge that better approximates human immunodeficiency virus (HIV) exposure.T wo important variables that can influence the apparent efficacy of preclinical human immunodeficiency virus (HIV)/ simian immunodeficiency virus (SIV) vaccines are the route of infection and the sequence of the challenge virus. For example, live attenuated SIV offers effective and consistent protection from intravenous challenge with a homologous virus but incomplete protection from intravenous challenge with a heterologous virus. This incomplete protection from heterologous challenge was observed after vaccination with several live attenuated SIV strains (e.g., SIVmac239⌬nef, SIVmac239⌬3, SIVsmE543⌬nef, and SIVmacC8), followed by challenge with different pathogenic SIV stocks (e.g., SIVsmE660, SHIV89.6p, SIV239/EnvE543, and SIVmac239) (1-6). Although those studies were each different, incomplete protection from an intravenous heterologous challenge was observed for both rhesus and cynomolgus macaques.The failure to offer complete protection from an intravenous challenge with a heterologous virus may be because some immune responses elicited by live attenuated SIV are localized to the mucosa and are not mobilized systemically at the time of challenge, making an intravenous challenge too stringent for testing of the efficacy of live attenuated SIV vaccines (7,8). Perhaps, immune responses elicited by a vaccine in an individual animal are sufficient to protect from mucosal challenge with a high dose of a heterologous virus, even if they cannot protect from intravenous challenge with the same virus.In this study, we wanted to test th...